Treatment for Erectile Dysfunction Based on Patient-Reported Outcomes: To Every Man the PDE5 Inhibitor that He Finds Superior

Author： Hedelin Hans Ströberg Peter

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.65, Iss.16, 2005-01, pp. : 2245-2251

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip Keel Christopher Klavens Meghan Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

Novel PDE5 inhibitors for the treatment of male erectile dysfunction

By Kalsi JS Bahadur G Muneer A Ozturk O Christopher N Ralph DJ Minhas S

Reproductive BioMedicine Online, Vol. 7, Iss. 4, 2003-10 ,pp. : 456-461

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer Bivalacqua Trinity J Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite

Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

By Limin Ma Johnsen Niels Hellstrom Wayne JG

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1427-1437

Informa Healthcare

Access to resources Recommend Favorite

A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction

By Cellek Selim Rees Rowland W Kalsi Jas

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1563-1573

Informa Healthcare

Access to resources Recommend Favorite